Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Suven Life Sciences Limited
Press Release Sep 18 2024
Business
Sep 18 2024
5 min read

Press Release Sep 18 2024

Suven Life Sciences Limited has informed the Exchange regarding a press release dated September 18, 2024, titled "Suven Life Sciences Announces Positive Topline Results from Phase-2a Proof-of-Concept Signal Detection Open Label Study of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder (MDD)".

View Attachment